Biosimilars are typically administered via injection, leading to complications due to the need for devices that mimic those still protected by patents. This results in a limited number of companies capable of providing suitable solutions. Successfully addressing this issue requires navigating a complex intellectual property landscape and securing difficult-to-obtain licenses
